Skip to main content
. 2022 Feb 12;13(5):1413–1447. doi: 10.1016/j.jcmgh.2022.02.006

Figure 16.

Figure 16

HNRNPM inhibition curbs immune escape and enhances PD-1 blockade by promoting CD8+ T cells activation phenotype.A, Schematic diagram of Hep1-6-OVA cells co-cultured with OTI cells. B, The flow cytometry analysis of IFN-γ+ or granzyme B+ CD8+ T cells between control and shHNRNPM groups. Data were from 3 independent experiments. ∗∗∗P < .001. P values were calculated using 1-way analysis of variance and Dunnett’s multiple comparison test. C, Schematic diagram of ASO and anti-PD-1 therapy in C57/BJ6 mice. D, Tumor inhibition by IgG (n = 6), HNRNPM-ASO (n = 6), anti-PD-1 (n = 6), or combination therapy (n = 6) in C57/BJ6 mice. ∗P < .05. P values were calculated using 1-way analysis of variance and Dunnett’s multiple comparison test. E, Survival analysis of IgG (n = 6), HNRNPM-ASO (n = 6), anti-PD-1 (n = 6), or combination therapy (n = 6) in C57/BJ6 mice. ∗P < .05. P values were calculated using 1-way analysis of variance and Dunnett’s multiple comparison test. F, The profiles of immune cells in tumors by HNRNPM-ASO, anti-PD-1 or combination therapy. G, CD8+ T cells infiltration in HNRNPM-ASO, anti-PD-1 or combination therapy groups. ∗∗P < .01. P values were calculated using 1-way analysis of variance and Dunnett’s multiple comparison test. H, The changes of Treg, IFNG+, GMZB+ CD8+ T cells in control, HNRNPM-ASO, anti-PD-1 or combination therapy groups in tumor-bearing C57/BJ6 mice. ∗∗∗P < .001. P values were calculated using 1-way analysis of variance and Dunnett’s multiple comparison test. I, The immune cells infiltration landscape of spleen in control, HNRNPM-ASO, anti-PD-1, or combination therapy groups in tumor-bearing C57/BJ6 mice. J, The mice weight between controls and HNRNPM-ASO group. ns, Non-significant. K, The relative expression of β-catenin in HNRNPM-ASO, anti-PD-1, or combination therapy groups. ∗∗∗P < .001. P values were calculated using 1-way analysis of variance and Dunnett’s multiple comparison test. L-M, The distribution of CTNNB1 mutation in PD-1 responders or non-responders. N, The study model diagram.